CD274 and head and neck squamous cell carcinoma: Despite preclinical data suggesting synergy between radiotherapy and immunotherapy [10,11,12], recent data on the addition of the PD-L1 mAb avelumab to standard of care chemoradiation for locally advanced HNSCC have been disappointing [13].